# A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

> **NCT06982924** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 136 (estimated)

## Conditions studied

- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- PD-L1 Positive

## Interventions

- **DRUG:** Limertinib+bevacizumab
- **DRUG:** Limertinib

## Key facts

- **NCT ID:** NCT06982924
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982924, "A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06982924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*